论文部分内容阅读
目的观察卡托普利联合前列地尔治疗糖尿病肾病的疗效。方法收集70例糖尿病肾病患者,并将其分成常规治疗组和联合治疗组两组,在常规降糖治疗的基础上,常规治疗组加用卡托普利,而联合治疗组加用卡托普利和前列地尔,经过3个月的治疗,观察治疗前后两组患者相关指标的变化。结果两组患者的血压、血糖变化均差异有统计学意义,P<0.05;而联合治疗组BUN、SCr及UAER变化均有统计学差异,P<0.05,其中Scr和UAER有显著差异,其P<0.01。而在两组间只有BUN、Scr及UAER变化值有统计学差异,P<0.05,其中Scr及UAER有显著差异,P<0.01。结论卡托普利联合前列地尔治疗糖尿病肾病有确切疗效,不但降低了血压,还能明显减少尿白蛋白的排出,值得在临床推广。
Objective To observe the curative effect of captopril combined with alprostadil on diabetic nephropathy. Methods Seventy patients with diabetic nephropathy were divided into two groups: conventional treatment group and combination treatment group. On the basis of routine hypoglycemic treatment, captopril was added to conventional treatment group, while combined treatment group was treated with captopril Lee and alprostadil, after 3 months of treatment, observed changes in patients before and after treatment-related indicators. Results There were significant differences in blood pressure and blood glucose between the two groups (P <0.05), while the changes of BUN, SCr and UAER in the combination therapy group were statistically different (P <0.05), and the differences of Scr and UAER were significant <0.01. Only BUN, Scr and UAER showed significant difference between the two groups (P <0.05), and Scr and UAER were significantly different (P <0.01). Conclusions Captopril in combination with alprostadil has the exact therapeutic effect on diabetic nephropathy. It not only reduces blood pressure, but also significantly reduces urinary albumin excretion, which deserves clinical promotion.